胰腺癌新辅助治疗的研究现状

doi:10.11904/j.issn.1002-3070.2022.01.012

Abstract

Abstract: Pancreatic cancer is the most malignant tumor of the digestive system.In recent years,the incidence of pancreatic cancer has increasing year by year.It is expected that pancreatic cancer will become the second leading cause of cancer death in developed countries in the next decade.Due to the late diagnosis and limited treatment options,the prognosis of pancreatic cancer is extremely poor.Only surgery is the only way to cure.In order to increase the surgical resection rate and improve the prognosis,neoadjuvant therapy has quietly become a hot topic in the treatment of pancreatic cancer.However,there is no standardized treatment plan for neoadjuvant treatment of pancreatic cancer.This article mainly discusses the research status of neoadjuvant treatment of pancreatic cancer.

Key words: Pancreatic cancer, Neoadjuvant therapy, Neoadjuvant chemotherapy, Neoadjuvant chemoradiotherapy

CLC Number:

R735.9

ZHANG Wenjing, LIU Jinshuang, WANG Dan, LI Qingwei, LI Zhiwei. Research status of neoadjuvant therapy for pancreatic cancer[J]. Journal of Practical Oncology, 2022, 36(1): 64-68.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2022.01.012

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2022/V36/I1/64

References

1 Lambert A,Schwarz L,Borbath I,et al.An update on treatment options for pancreatic adenocarcinoma[J].Ther Adv Med Oncol,2019,11:1758835919875568.
2 Saito K,Isayama H,Sakamoto Y,et al.A phase II trial of gemcitabine,S-1 and LV combination(GSL)neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancer[J].Med Oncol,2018,35(7):100.
3 Napolitano F,Formisano L,Giardino A,et al.Neoadjuvant treatment in locally advanced pancreatic cancer(LAPC)patients with FOLFIRINOX or Gemcitabine NabPaclitaxel:a single-center experience and a literature review[J].Cancers(Basel),2019,11(7):981.
4 范晓娜,王丹,黎清炜,等.胰腺癌术后辅助药物治疗的研究进展[J].实用肿瘤学杂志,2020,34(3):249-253.
5 Siegel RL,Miller KD,Jemal A.Cancer statistics,2019[J].CA Cancer J Clin,2019,69(1):7-34.
6 Chen-Zhao X,Hernando O,López M,et al.A prospective observational study of the clinical and pathological impact of stereotactic body radiotherapy(SBRT)as a neoadjuvant strategy of chemoradiation in pancreatic cancer[J].Clin Transl Oncol,2020,22(9):1499-1505.
7 Motoi F,Kosuge T,Ueno H,et al.Randomized phase Ⅱ/Ⅲ trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer(Prep-02/JSAP05)[J].Jpn J Clin Oncol,2019,49(2):190-194.
8 Seufferlein T,Ettrich TJ.Treatment of pancreatic cancer—neoadjuvant treatment in resectable pancreatic cancer(PDAC)[J].Transl Gastroenterol Hepatol,2019,4:21.
9 Motoi F,Unno M.Neoadjuvant treatment for resectable pancreatic adenocarcinoma:What is the best protocol?[J].Ann Gastroenterol Surg,2020,4(2):100-108.
10 Abi Jaoude J,Kouzy R,Nguyen ND,et al.Radiation therapy for patients with locally advanced pancreatic cancer:Evolving techniques and treatment strategies[J].Curr Probl Cancer,2020,44(6):100607.
11 Xiang M,Heestand GM,Chang DT,et al.Neoadjuvant treatment strategies for resectable pancreas cancer:a propensity-matched analysis of the national cancer database[J].Radiother Oncol,2020,143:101-107.
12 Gao S,Zhu X,Shi X,et al.Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer:study protocol of a prospective,randomized phase II trial(BRPCNCC-1)[J].Radiat Oncol,2019,14(1):52.
13 Pan L,Fang J,Tong C,et al.Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer:a systematic review and meta-analysis[J].World J Surg Oncol,2019,18(1):1.
14 Sho M,Akahori T,Tanaka T,et al.Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer[J].J Hepatobiliary Pancreat Sci,2013,20(2):197-205.
15 Maurel J,Sánchez-Cabús S,Laquente B,et al.Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer(GEMCAD 10-03 trial)[J].Cancer Chemother Pharmacol,2018,82(6):935-943.
16 Chiaro DM,Soreide K.Trials and tribulations of neoadjuvant therapy in pancreatic cancer[J].Br J Surg,2018,105(11):1387-1389.
17 Ye M,Zhang Q,Chen Y,et al.Neoadjuvant chemotherapy for primary resectable pancreatic cancer:a systematic review and meta-analysis[J].HPB(Oxford),2020,22(6):821-832.
18 Roland CL,Yang AD,Katz MH,et al.Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer[J].Ann Surg Oncol,2015,22(4):1168-1175.
19 Nagakawa Y,Hosokawa Y,Nakayama H,et al.A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement[J].Cancer Chemother Pharmacol,2017,79(5):951-957.
20 Murphy JE,Wo JY,Ryan DP,et al.Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer:a phase 2 Clinical Trial[J].JAMA Oncol,2019,5(7):1020-1027.
21 Vidri RJ,Vogt AO,Macgillivray DC,et al.Better defining the role of total neoadjuvant radiation:changing paradigms in locally advanced pancreatic cancer[J].Ann Surg Oncol,2019,26(11):3701-3708.
22 Jang JY,Han Y,Lee H,et al.Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer a prospective,randomized,open-label,multicenter phase 2/3 trial[J].Ann Surg,2018,268(2):215-222.
23 Galindo J,Gabrielli M,Guerra JF,et al.Neoadjuvant chemoradiation therapy for borderline pancreatic adenocarcinoma:report of two cases[J].World J Surg Oncol,2013,11:37.
24 Passardi A,Scarpi E,Neri E,et al.Chemoradiotherapy(Gemox Plus Helical Tomotherapy)for unresectable locally advanced pancreatic cancer:a phase II study[J].Cancers(Basel),2019,11(5):663.
25 Pipas JM,Zaki BI,McGowan MM,et al.Neoadjuvant cetuximab,twice-weekly gemcitabine,and intensity-modulated radiotherapy(IMRT)in patients with pancreatic adenocarcinoma[J].Ann Oncol,2012,23(11):2820-2827.
26 Belfiore MP,Ronza FM,Romano F,et al.Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer:our preliminary experience[J].Int J Surg,2015,21(suppl 1):34-39.
27 Yu Y,Zheng P,Chen Y,et al.Advances and challenges of neoadjuvant therapy in pancreatic cancer[J].Asia Pac J Clin Oncol,2020[online ahead of print].

[1]	LIU Jinshuang, ZHAGN Wenjing, LI Qingwei, LI Zhiwei. Research progress of therapies combined immune checkpoint inhibitors in pancreatic cancer [J]. Journal of Practical Oncology, 2022, 36(1): 49-53.
[2]	WANG Liangliang, DING Gaoheng, CHEN Lili, WU Jianjun, LIU Yuqin, WEI Xingmin. Trends of incidence and mortality of pancreatic cancer in Gansu cancer registration areas,2009—2015 [J]. Journal of Practical Oncology, 2021, 35(3): 200-206.
[3]	WANG Jianyu, ZHANG Xianyu, PANG Da. Influencing factors of neoadjuvant chemotherapy for Luminal A type breast cancer [J]. Journal of Practical Oncology, 2021, 35(2): 131-136.
[4]	YAO Kefei,ZHANG Bomiao,CUI Binbin. Research progress of selective lateral lymph node dissection in low rectal cancer [J]. Journal of Practical Oncology, 2021, 35(1): 69-72.
[5]	LIU Hong, LU Hailing, CAI Li. Advances in imaging prediction of prognosis and neoadjuvant chemotherapy response in breast cancer patients [J]. Journal of Practical Oncology, 2020, 34(6): 535-539.
[6]	XIE Xianxin,WEI Jun,QIU Jiaxin,WANG Cong,JIANG Daqing. Analysis of histopathological information and prognosis of residual tumor in neoadjuvant chemotherapy for breast cancer [J]. Journal of Practical Oncology, 2020, 34(3): 225-231.
[7]	FAN Xiaona,WANG Dan,LI Qingwei,LI Zhiwei. Advances in research on adjuvant drug threapy for postoperative pancreatic cancer [J]. Journal of Practical Oncology, 2020, 34(3): 249-253.
[8]	YANG Lei, SU Dan, LOU Changjie. Diagnosis and treatment of patients with hepatobiliary and pancreatic malignant tumor during and after the epidemic of corona virus disease 2019 [J]. Journal of Practical Oncology, 2020, 34(2): 107-110.
[9]	LI Shan,ZHAO Chunbo,QIAO Wenbo. Progress in the application of intraoperative radiotherapy in pancreatic cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 280-283.
[10]	LUO Gan, YI Chao, YIMAMUMAIMAITIJIANGo Abula, XU Lin, YIN Jiwei, DING Wei. Expression of Notch signaling pathway in pancreatic cancer and its role [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 1-7.
[11]	LI Yujiao, SHANG Naijian. Research progress of imaging evaluation of neoadjuvant chemotherapy in breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 63-67.
[12]	CHEN Li, ZHANG Yuxin, ZUO Yanjiao, MA Fei, SONG Hongjiang, XUE Yingwei. The comparison of clinical efficacy of SOX and XELOX in the neoadjuvant chemotherapy for advanced gastric carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 23-30.
[13]	YANG Meijian, BAO Yingna, ZHAO Jianguo. Advances in neoadjuvant therapy of rectal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(5): 453-457.
[14]	ZHAO Xiangxuan,WEN Feng,LU Zaiming. The role of apoptosis in pancreatic cancer therapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(4): 375-379.
[15]	DAI Meng, LI Rui, LIU Guiting, LIANG Jinlong, FENG Jinfa, XU Shanyong. The feasibility analysis of breast conserving surgery after neoadjuvant chemotherapy in the treatment with advanced breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 109-113.

Research status of neoadjuvant therapy for pancreatic cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments